Prospective CoHoRt Of Non-infectious Intermediate, pOsterior or panuveitiS (CHRONOS)

prospective, cohort, longitudinal, multicenter, non-randomized study of patients with non-infectious posterior segment uveitis or panuveitis, with a group of control patients (scheduled for cataract or vitreoretinal surgery) and constitution of biological collection.

Description of the clinical characteristics and evolution in a large cohort of patients with non-infectious uveitis, allowing to identify prognostic or predictive factors of response after treatment of these different forms of non-infectious uveitis of the posterior segment or panuveitis (factors that are currently not well known). Uveitis patients: Blood sample (20ml): Additional 20 ml blood sample during the first visit and potentially during follow-up (if necessary) for the purpose of the biological collection; Ocular sample (aqueous humor, vitreous): if required by the clinical context for the needs of the biological collection; Specific imaging: adaptive optics or Doppler holography, these procedures will be indicated on a case-by-case basis, at the investigator's discretion, and concern only patients with inflammatory vascular damage (5 to 10% of patients in the uveitis cohort); Quality of Life NEI-VFQ 25: provided at the inclusion visit and at follow-up visits M3-V2, M12-V5 and M24-V7. Control patients: Blood sample (20ml): Additional 20 ml blood sample during the inclusion visit at the time of the surgical scheduled procedure for the needs of the biological collection; Ocular sample (aqueous humor, vitreous): considered as surgical waste, the tissue residues will be collected during the scheduled surgical procedure for cataract or vitreoretinal surgery for the needs of the biological collection;

Uveitis Patients: intermediate, posterior or panuveitis noninfectious uveitis with Inflammatory activity requiring treatment with either one or more of the following: Systemic corticosteroids or periocular or intravitreal injections of corticosteroids Immunosuppressants: methotrexate, azathioprine, ciclosporine…. Biotherapy: infliximab, adalimumab, tocilizumab

Uveitis patients: Blood sample (20ml): Additional 20 ml blood sample during the first visit and potentially during follow-up (if necessary) for the purpose of the biological collection; Ocular sample (aqueous humor, vitreous): if required by the clinical context for the needs of the biological collection; Specific imaging: adaptive optics or Doppler holography, these procedures will be indicated on a case-by-case basis, at the investigator's discretion, and concern only patients with inflammatory vascular damage (5 to 10% of patients in the uveitis cohort); Quality of Life NEI-VFQ 25: provided at the inclusion visit and at follow-up visits M3-V2, M12-V5 and M24-V7.

To develop an imaging database of Non-Infectious Uveitis of the posterior segment (NIUPS) using multimodal imaging

To estimate the current costs of treatment by ensuring linkage of cohort patients to the national claims database

Inclusion Criteria: UVEITIS Patients: Adult patients (≥ 18 years); Non-infectious uveitis; Intermediate, posterior or panuveitis; Inflammatory activity requiring treatment with either one or more of the followings: Systemic corticosteroids or periocular or intravitreal injections of corticosteroids; Immunosuppressants: methotrexate, azathioprine, cyclosporine, etc.; Biotherapy: infliximab, adalimumab, tocilizumab; Patients with health insurance; Written Informed consent obtained at enrolment in the study. Control patients: Adult patients (≥ 18 years); Scheduled patients ( Non-urgente procedure) for cataract or vitreoretinal surgery; Patients with health insurance; Written Informed consent obtained at enrolment in the study. Exclusion Criteria: Uveitis Patients: Isolated anterior uveitis ; Inactive disease defined as: Absence of inflammatory chorioretinal and/or inflammatory retinal vascular lesion; Anterior chamber cell grade< 0.5+; Vitreous haze grade <0.5+; Pregnant or breastfeeding woman at the inclusion visit; Patient under legal protection (" curatelle " or " tutelle "); Patient denied freedom by a legal or administrative order. Control patients: Pregnant or breastfeeding woman; Unscheduled (urgent) cataract or vitreoretinal surgery; Patient under legal protection (" curatelle " or " tutelle "); Patient denied freedom by a legal or administrative order.